Company intelligence / Profile preview

DANNCE.AI

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

DANNCE.AI’s platform demonstrates clinical utility in objectively quantifying movement impairment in Parkinson’s patients, with pilot results and validation studies supporting its accuracy and sensitivity over clinician-derived scoring.

Therapeutic areas: NeurologyPsychiatry
Modalities: Non-pharmacological therapyDeviceDigital biomarker platform
Industry: Physiological Monitoring

Partnerships

Merck Digital Sciences StudioLDV CapitalGlasswing VenturesThe Leo Lion CompanyDuke Capital PartnersHarvard University (technology origin)Duke University (technology origin)

Beyond the preview

Go deeper on DANNCE.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DANNCE.AI.

Explore the full profile